IL320955A - Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile - Google Patents
Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficileInfo
- Publication number
- IL320955A IL320955A IL320955A IL32095525A IL320955A IL 320955 A IL320955 A IL 320955A IL 320955 A IL320955 A IL 320955A IL 32095525 A IL32095525 A IL 32095525A IL 320955 A IL320955 A IL 320955A
- Authority
- IL
- Israel
- Prior art keywords
- difficile
- eliciting
- clostridium
- methods
- immune response
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263387100P | 2022-12-13 | 2022-12-13 | |
| US202363485995P | 2023-02-20 | 2023-02-20 | |
| US202363598556P | 2023-11-14 | 2023-11-14 | |
| PCT/IB2023/062488 WO2024127215A2 (en) | 2022-12-13 | 2023-12-11 | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320955A true IL320955A (en) | 2025-07-01 |
Family
ID=89662086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320955A IL320955A (en) | 2022-12-13 | 2023-12-11 | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240189410A1 (en) |
| EP (1) | EP4633669A2 (en) |
| JP (2) | JP7817503B2 (en) |
| KR (1) | KR20250120405A (en) |
| CN (1) | CN120475988A (en) |
| AU (1) | AU2023393199A1 (en) |
| CO (1) | CO2025007834A2 (en) |
| IL (1) | IL320955A (en) |
| MX (1) | MX2025006896A (en) |
| PE (1) | PE20251914A1 (en) |
| TW (1) | TW202438104A (en) |
| WO (1) | WO2024127215A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI909678B (en) * | 2023-09-13 | 2025-12-21 | 美商輝瑞股份有限公司 | Methods for producing an adjuvant |
| TW202612726A (en) * | 2024-06-12 | 2026-04-01 | 美商輝瑞股份有限公司 | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US628371A (en) | 1898-09-10 | 1899-07-04 | Clark W Thomas | Machine for making berry-boxes. |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| EP0092574B1 (en) | 1981-10-23 | 1992-04-29 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and methods of making same |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DE4321946A1 (en) | 1993-07-01 | 1995-01-12 | Hoechst Ag | Methylphosphonic acid esters, process for their preparation and their use |
| US5658738A (en) | 1994-05-31 | 1997-08-19 | Becton Dickinson And Company | Bi-directional oligonucleotides that bind thrombin |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| DK1187629T3 (en) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| EP1425040A2 (en) | 2001-09-14 | 2004-06-09 | Cytos Biotechnology AG | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| JP2008506789A (en) | 2004-07-18 | 2008-03-06 | シーエスエル、リミテッド | Immunostimulatory complex and oligonucleotide formulation for inducing enhanced interferon-gamma response |
| AU2008299885C1 (en) * | 2007-09-14 | 2015-06-25 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing clostridium difficile toxoids A and B |
| KR101329374B1 (en) | 2008-12-09 | 2013-11-14 | 콜레이 파마시티컬 그룹, 인코포레이티드 | Immunostimulatory oligonucleotides |
| DK2424562T3 (en) | 2009-04-30 | 2015-12-07 | Coley Pharm Group Inc | Pneumococcal vaccine and uses thereof |
| AR086199A1 (en) | 2011-04-22 | 2013-11-27 | Wyeth Llc | COMPOSITIONS RELATED TO A MUTANT DIFFICILE CLOSTRIDIUM TOXIN AND ITS METHODS |
| BR122016023101B1 (en) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polypeptide, immunogenic composition comprising it, as well as recombinant cell derived from Clostridium difficile |
| EP2928489B1 (en) * | 2012-12-05 | 2019-02-27 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| CN107124869B (en) * | 2014-03-25 | 2022-04-01 | 美国政府陆军部 | Non-toxic adjuvant formulations comprising a liposomal composition comprising monophosphoryl lipid a (mpla) and a saponin |
| US10555992B2 (en) | 2017-05-31 | 2020-02-11 | University Of South Florida | Immunogenic proteins against clostridium difficile |
| EP3678695A1 (en) * | 2017-09-08 | 2020-07-15 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
| MX2020003756A (en) | 2017-09-28 | 2020-07-29 | Pfizer | COMPOSITIONS AND METHODS TO OBTAIN AN IMMUNE RESPONSE AGAINST CLOSTRIDIUM DIFFICILE. |
| WO2020201985A1 (en) | 2019-04-01 | 2020-10-08 | Pfizer Inc. | Compositions and methods for eliciting an immune response against clostridium difficile |
| WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| GB2600468A (en) * | 2020-10-30 | 2022-05-04 | Excivion Ltd | Adjuvant composition |
| AU2023235562B2 (en) | 2022-03-14 | 2026-07-30 | Pfizer Inc. | Methods for producing an adjuvant |
-
2023
- 2023-12-11 AU AU2023393199A patent/AU2023393199A1/en active Pending
- 2023-12-11 WO PCT/IB2023/062488 patent/WO2024127215A2/en not_active Ceased
- 2023-12-11 CN CN202380089861.9A patent/CN120475988A/en active Pending
- 2023-12-11 TW TW112148105A patent/TW202438104A/en unknown
- 2023-12-11 PE PE2025001228A patent/PE20251914A1/en unknown
- 2023-12-11 EP EP23844115.8A patent/EP4633669A2/en active Pending
- 2023-12-11 US US18/535,116 patent/US20240189410A1/en active Pending
- 2023-12-11 JP JP2025534132A patent/JP7817503B2/en active Active
- 2023-12-11 IL IL320955A patent/IL320955A/en unknown
- 2023-12-11 KR KR1020257022942A patent/KR20250120405A/en active Pending
-
2025
- 2025-06-11 CO CONC2025/0007834A patent/CO2025007834A2/en unknown
- 2025-06-12 MX MX2025006896A patent/MX2025006896A/en unknown
-
2026
- 2026-02-05 JP JP2026017439A patent/JP2026082987A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7817503B2 (en) | 2026-02-18 |
| AU2023393199A1 (en) | 2025-05-29 |
| JP2025541207A (en) | 2025-12-18 |
| TW202438104A (en) | 2024-10-01 |
| WO2024127215A3 (en) | 2024-11-07 |
| JP2026082987A (en) | 2026-05-19 |
| MX2025006896A (en) | 2025-07-01 |
| WO2024127215A2 (en) | 2024-06-20 |
| EP4633669A2 (en) | 2025-10-22 |
| CN120475988A (en) | 2025-08-12 |
| CO2025007834A2 (en) | 2025-06-26 |
| KR20250120405A (en) | 2025-08-08 |
| US20240189410A1 (en) | 2024-06-13 |
| PE20251914A1 (en) | 2025-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4458975A3 (en) | Hbv vaccines and methods treating hbv | |
| IN2014DN08830A (en) | ||
| WO2013006842A3 (en) | Self-replicating rna prime - protein boost vaccines | |
| WO2011109833A3 (en) | Induced dendritic cell compositions and uses thereof | |
| IL307749A (en) | Compositions and method for optimized peptide vaccines using residue optimization | |
| MY202505A (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| WO2011139769A3 (en) | Immunogenic compositions and methods for treating neoplasia | |
| EP4171574A4 (en) | Compositions and methods for inducing an immune response against coronavirus | |
| WO2019118974A3 (en) | Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms | |
| PH12015501716B1 (en) | Anti-mycoplasma spp. subunit vaccine | |
| MX2020005554A (en) | Zika vaccines and immunogenic compositions, and methods of using the same. | |
| CA3276659A1 (en) | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile | |
| WO2012174455A3 (en) | Group a streptococcus multivalent vaccine | |
| MX2025006896A (en) | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile | |
| HK1248541A1 (en) | Leptospira immunoprotective proteins and methods of identification and use thereof | |
| EP4247401A4 (en) | Compositions and methods for optimized peptide vaccines | |
| ZA202203368B (en) | Immunogenic compositions against enteric diseases and methods for its preparation thereof | |
| SG11202106494RA (en) | Compositions, methods and uses for eliciting an immune response | |
| NZ704204A (en) | Method of providing protective immunity against heterologous leptospira strains | |
| MX2017014666A (en) | Methods for immunizing against clostridium difficile. | |
| HK40087478A (en) | Immunogenic constructs, compositions, and methods for inducing immune response | |
| ZA201905875B (en) | Immunostimulating compositions and uses therefore | |
| EP3852796A4 (en) | Vaccine, method of vaccination against clostridium difficile | |
| AU2022903749A0 (en) | Components, compositions, and methods for inducing an immune response | |
| PH12022550081A1 (en) | Ehrlichia vaccines and immunogenic compositions |